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Radical prostatectomy with and without adjuvant radiotherapy 
for pT3N0 prostate cancer 
Zbigniew Petrovich
P u r p o s e:  From 30 to over 50% of patients with cancer of the prostate (CaP) are found at surgery (RP) to have more
advanced disease.  Postoperative irradiation (RT) has been systematically investigated for patients with pT3N0 tumors and its
value is presented in this report.
Pa t i e n t s  a n d  m e t h o d s:  A total of 622 pT3N0 CaP patients were treated with RP.  Of these, 199 (32%) with lower risk
factors received RP alone while 423 (68%) with higher risk factors received a planned postoperative RT (median 48 Gy).
These higher prognostic factors included clinical stage, p=0.001, pathological stage, p=0.001, preoperative PSA level,
p<0.0001, and Gleason score, p=0.18. Median follow up for all patients was 7 years.
R e s u l t s:  The 5- and 10-year actuarial survival was 92 and 73%, respectively for RP+RT patients and nearly identical for
those in RP alone group, p=0.73.  The 5-and 10-year disease-free survival (DFS) (PSA<0.05 ng/ml) was 69 and 51%,
respectively for the former and 71 and 60%, respectively for the latter group.  There was no significant difference in DFS
between the two treatment groups by pathologic stage and Gleason score, p=0.77.  Preoperative PSA <10 vs. 10-25 vs.
>25 ng/ml did not influence overall survival but PSA >25 ng/ml was predictive of DFS, p=0.02.  In multivariate analysis
Gleason score was the most important predictor for overall and DFS survival, p=0.00002 while pathologic stage was
predictive of clinical recurrence and DFS, p<0.00001.  Patients who had RP alone experienced a similar incidence of local
failure as RP-RT patients who had significantly worse prognostic factors.  Postoperative RT was well tolerated and did not add
to the incidence of surgical complications.
C o n c l u s i o n s:  We hypothesize that planned postoperative RT helped to reduce the expected incidence of local recurrence
and improved DFS to equal that of a lower risk patients treated with RP alone.
Radykalna prostatektomia z – lub bez – adiuwantowà radiotreapià u chorych na raka prostaty 
w stopniu zaawansowania pT3N0
C e l  p r a c y.  Podczas wykonywania radykalnej prostatektomii u 30-50% chorych stwierdza si´ wy˝szy, ni˝ zak∏adano wst´p-
nie, stopieƒ zaawansowania choroby nowotworowej. Celem niniejszej pracy jest przedstawienie wyników leczenia chirurgicz-
nego, uzupe∏nionego o pooperacyjnà radioterapi´ u chorych z rakiem prostaty w stopniu pT3N0.
M a t e r i a ∏  i m e t o d y.  622 chorych z rakiem prostaty w stopniu pT3N0 poddano radykalnej prostatektomii (RP). U 199
(32%) spoÊród nich stwierdzono mniej istotne czynniki ryzyka i ograniczono leczenie tylko do post´powania chirurgicznego,
u pozosta∏ych 423 (68%) stwierdzono obecnoÊç czynników podwy˝szonego ryzyka i przeprowadzono pooperacyjnà radiote-
rapi´ (PR) (mediana 48 Gy). Za czynniki podwy˝szonego ryzyka uznano: stopieƒ zaawansowania klinicznego (p=0,001), sto-
pieƒ zaawansowania patologicznego (p=0,001), poziom PSA przed operacjà (p<0,0001) oraz stopieƒ wg skali Gleasona
(p=0,18). Âredni okres obserwacji chorych wyniós∏ 7 lat.
W y n i k i.  5- i 10-letnie prze˝ycie osiàgn´∏o, odpowiednio, 92 i 71% chorych leczonych RP + PR. Wyniki w grupie leczonej
tylko RP by∏y niemal identyczne (p=0,73). 5- i 10-letni okres prze˝ycia bez objawów choroby (DFS) (PSA<0,05 ng/ml) osià-
gn´∏o, odpowiednio, 69% i 51% chorych z grupy RP + PR oraz, odpowiednio, 71% i 60% chorych z grupy RP. DFS nie ró˝-
ni∏o si´ w obu grupach w zale˝noÊci od stopnia zaawansowania patologicznego i od stopnia wg skali Gleasona (p=0,77). Nie
obserwowano zwiàzku pomi´dzy poziomem PSA przed operacjà (w granicach <10 vs. 10-25 vs. >25 ng/ml), a okresem prze-
˝ycia ca∏kowitego, ale poziom PSA przed operacjà >25 ng/ml by∏ istotnym czynnikiem rokowniczym dla DFS. Analiza wie-
loczynnikowa wykaza∏a, ˝e stopieƒ wg skali Gleasona by∏ najwa˝niejszym czynnikiem prognostycznym dla prze˝ycia ca∏kowi-
tego i DFS (p=0,00002), podczas gdy stopieƒ zaawansowania patologicznego by∏ czynnikiem prognostycznym dla wznowy kli-
nicznej i DFS (p<0,00001). W grupie chorych, u których leczenie by∏o ograniczone do RP wznowa miejscowa by∏a równie
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Adenocarcinoma of the prostate (CaP) is the most
common malignancy in the US (Table I) and its incidence
is the highest in the world [1]. The incidence of CaP is
increasing with the age of population, being very
uncommon (1 in 10,000) among those under the age of
40 years and very common (12.5%) in males between
60 and 79 years of age. The American males have one
in six lifetime chance of developing CaP. CaP is also
an important cancer in the European Community being
responsible for 9% of all cancer deaths in males [2]. On
the other hand, this tumor while common in Poland is
clearly of a lesser importance in that country than the
primary lesions of the lung or cervix [1]. Mortality due
to CaP was in 2000, 11.2 per 100,000 population in
Poland, which ranked 32nd in the world while that of
the US was 17.9 per 100,000, which ranked 18th in
the world (Table II) [1]. In the 1990’s the incidence of CaP
in the US has stabilized and in 2002 it is expected to be
diagnosed in 189,000 patients with 30,200 of these are
estimated to die of this disease in the same year.
The management of CaP in the US is one of the
success stories in the American oncology. Most (84%)
patients are being diagnosed with local disease with only
6% presenting with distant metastasis at diagnosis [1].
Major improvements in surgery and radiotherapy as well
as the availability of an effective hormonal management
over the past 25 years resulted in a steep improvement in
survival. The 5-year relative survival for all stages in the
US for the period of 1974-1976 was 73% and for the
period of 1992-1997 it was 96% [1]. As the proportion
of patients diagnosed with tumor confined to the prostate
increased, there has been a greater interest in treating
patients with RP rather than with definitive radiotherapy.
This increased emphasis on RP is particularly evident
among younger patients. In patients < 55 years of age
who were diagnosed in the US with localized disease the
incidence of RP in 1985 was 35% and it increased to 69%
in 1990 [3]. Increased incidence of RP affected all age
groups except for those > 80 years of age (Table III).
There is no prospective randomized trial comparing
treatment outcomes in CaP patients managed with
definitive radiotherapy or surgery. The prospect for such
a trial remains poor. It is of interest to review outcomes in
146,979 patients treated for CaP in the US between 1973
and 1990 [4]. Of the 107,103 patients with locoregional
disease, 60% had RP, 12% had radiotherapy alone, 16%
had RT+RP combination and the remaining 12%
received no definitive therapy. The median survival was
cz´sta, co w grupie chorych leczonych RP + PR, pomimo, ˝e ci ostatni mieli zdecydowanie gorsze czynniki prognostyczne. PR
by∏a dobrze tolerowana przez chorych i nie przyczyni∏a si´ do zwi´kszenia cz´stoÊci wyst´powania powik∏aƒ chirurgicznych.
W n i o s k i.  Sàdzimy, ˝e zastosowanie planowej pooperacyjnej radioterapii przyczyni∏o si´ do zredukowania przewidywanej cz -´
stoÊci wystàpienia wznów miejscowych i pozwoli∏o poprawiç DFS, zrównujàc je z wartoÊciami obserwowanymi u chorych,
u których nie stwierdzano obecnoÊci czynników podwy˝szonego ryzyka, a którzy byli leczeni tylko RP. W celu obiektywnej oce-
ny roli radioterapii adiuwantowej u chorych z rakiem prostaty pT3N0 konieczne jest przeprowadzenie badaƒ randomizowa-
nych.
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Table I. Estimated incidence and deaths from GU cancer in the US in 2002 [1]
Site Incidence Mortality
M+F Male Female M+F Male Female
Prostate 189,000 189,000 - 30,200 30,200 -
Bladder 56,500 41,500 15,000 12,600 8,600 4,000
Kidney+ 34,200 20,700 13,500 12,300 7,600 4,700
Testis 7,500 7,500 - 400 400 -
Other 1,200 1,200 - 200 200 -
All GU site 288,400 259,900 28,500 55,700 47,000 8,700
All cancer 1284,900 637,500 647,400 555,500 288,200 267,300
Table II. Death rate per 100,000 population in four selected countries in 2000 [1]
Country All sites Prostate Lung Breast
M F M M F F
Poland 205 (6)* 111 (16) 11 (32) 71(2) 11 (15) 17 (30)
USA 162 (22) 116 (10) 18 (18) 53 (13) 27 (1) 21 (12)
Hungary 272 (1) 142 (1) 18 (18) 86 (1) 20 (5) 25 (7)
Germany 177 (16) 117 (8) 18 (15) 46 (20) 10 (18) 24 (8)
* Rank in the world
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103 months for RT treated patients, 93 months for
RT+RP, 73 months for RP alone and 50 months for those
receiving no specific therapy.
Reported modern studies with treatment results
following RP in patients with localized CaP demonstrated
an excellent overall and disease-free survival (DFS) as
well as a low incidence of toxicity and good quality of
life [5]. Surgical results in patients with high (7-10)
Gleason score, however, are disappointing with the 5-
year DFS of only 33% [6]. Treatment results obtained
with contemporary radiotherapy have also been excellent
and the treatment was compatible with virtually
unchanged quality of life in an overwhelming majority of
patients [7-10]. It is to be noted that radiotherapy treated
patient population typically represents patients with
greater risk factors for tumor recurrence than those
selected for surgical therapy.
In spite of major efforts to define accurately the
true tumor extent prior to surgery or radiotherapy,
this accurate definition remains an elusive goal.
The primary reason for it is our inability to diagnose
preoperatively microscopic extraprostatic tumor extension
in addition to not being able to accurately predict
positive surgical margins [11, 12]. The incidence of
pathological stage pT3N0 varies widely in the published
reports. It ranges from a low of <20% to a high of >50%
[11-20].
Patients who are diagnosed with pT3N0 disease
present a therapeutic dilemma since the optimal treat-
ment for it is far from being settled. Some advocate no
adjuvant therapy because of an unpredictable incidence of
tumor recurrence; others recommend adjuvant treatment
consisting of radiotherapy while hormonal therapy alone
is also being supported [21-23]. It has been clearly
established that the incidence of tumor recurrence in
pT3N0 patients depends on a number of important
prognostic factors such as: 1. Pathological stage; 2.
Gleason score; 3. The number of positive surgical
margins; 4. Preoperative PSA level; 5. Preoperative tumor
volume; 6. Seminal vesicle invasion; 7. Perineural
invasion; 8. Perivascular invasion; and 9. Lymphatic
invasion [11-20]. A considerable experience is required to
evaluate the above risk factors and recommend the most
optimal treatment in a given patient.
The purpose of this report is to present this medical
center experience with the planned management of
patients diagnosed with pT3N0M0 disease.
Materials and methods
Pa t i e n t  c h a r a c t e r i s t i c s
From 1976 to 1998, a total of 1,976 patients were treated with
RP in this medical center. Of these 622 (31%) had pT3N0
disease and are the subject of this report. In our earlier reports,
we have identified pT3N0 patients who had a lower risk of tumor
recurrence and were recommended not to receive adjuvant
radiotherapy while those with a higher probability of failure
received a planned course of adjuvant RT [24-26]. Due to an
encouraging treatment results noted in our interim reports
a progressively greater proportion of pT3N0 patients were
considered for planned RT [24-26]. Patient age ranged from 40
to 84 years with the median age of 66 years for RP+RT and 67
years for RP alone patients. Since patients were selected for
adjuvant RT by the study two urologists it is not surprising that
they had a higher probability of factors adversely influencing
prognosis than those treated with RP alone. These important
prognostic factors included: clinical stage, p=0.001, pathological
stage, p=0.001, preoperative PSA level, p<0.0001 and Gleason
score, p=0.24 (Table IV). RP+RT patients had a greater
probability to be diagnosed with clinical stage T3, had a higher
incidence of seminal vesicle involvement and a higher median
preoperative serum PSA level (Table IV). All patients had
histological confirmation of diagnosis of CaP. Gleason score
was available in 420 (99.3%) of RP+RT and in 196 (98.5%) of
RP patients (Table IV).
Patients considered for surgery had detailed general and
urological history and physical examination performed. This
included digital rectal examination (DRE). Transrectal
ultrasound examination was performed in all study patients with
other imaging studies performed on as needed basis. PSA was
routinely available since 1987 and 532 (85.5%) study patients had
preoperative serum level measured. PSA undetectable level was
defined as <0.05 ng/ml. PSA failure was defined as two
determinations of >0.05 ng/ml. Important details of PSA
techniques used in this study have been reported (24-26). Local
failure was biopsy confirmed while distant metastases were
diagnosed based on imaging studies. Patients were staged
according to the American Joint Committee Staging System of
1997 [27]. Follow-up schedule was as follows: every three months
in the first post-treatment year, every four months in the second
year, every six months in the third year and annually thereafter.
Prior to each follow-up visit PSA level was obtained. Interim
history was obtained and physical examination performed
including DRE. Median follow-up for all patients was 73 months
with a range from 2 to 20 years. RP+RT patients had a median
follow-up of 84 months and RP alone patients had a median
follow-up of 59 months.
Tr e a t m e n t
Surgery
Patients selected for RP had to meet the following criteria: 1.
Good general condition, 2. Expected survival >10 years, and 3.
Capsule confined disease. Modified radical retropubic
prostatectomy with limited pelvic lymphadenectomy was
performed in 55% of RP+RT and in 33% of RP alone patients
while bilateral nerve sparing procedure was performed in 38% of
the former and in 59% of the latter patients. The remaining
patients of each group were treated with a unilateral nerve
sparing procedures. Details on surgical techniques used in this
study have been reported elsewhere [21, 28-31].
Radiotherapy
Radiotherapy was scheduled to begin from 42 to 90 days of RP.
This period of time was felt to be necessary to allow for healing,
Table III. Radical prostatectomy for CaP patients  1985-1990 [3]
Age (years) 1985 1990
N % N %
< 55 32 35 340 69
55- 64 193 27 1,999 55
65- 69 197 21 2,213 46
> 70 130 9 2,045 24
Total 552 21 6,597 43
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particularly at the site of anastomosis. Patients were to receive 45
Gy at 1.8 Gy daily fractions for pT3aN0 and 54 Gy for pT3bN0
tumors. The median radiation dose given was 48 Gy. Radiation
dose was defined to the 95% isodose line. A total of 290 (69%)
patients received their treatment with the 20 MV photon
beam. The remaining patients were treated with 6 to 15 MV
photon beams. The four-field “box technique” was used in the
treatment of 75% of patients with the remainder treated with
a combination of fixed fields and bilateral arc rotation. Prior to
1992, radiation portals were shaped with the use of custom
shields and in the most recent period with a multi leaf collimator.
An average field size was 11x11 cm with an effective area of
treatment about 90 cm2. The volume of interest included the
prostatic fossa and its immediate vicinity with no attempt being
made to treat the regional lymphatics. Details of the radiation
techniques used in this study as well as details on data analysis
have been published [31, 32].
Results
The overall 5- and 10-year actuarial survival for RP+RT
patients was 92 and 73%, respectively, which was very
similar to the long-term survival obtained in RP patients,
p=0.73 (Table V). The 5- and 10-year DFS for RP+RT
patients was 69 and 52%, respectively and again there
was no significant difference in DFS between to two
treatment groups, p=0.19 (Table V). Likewise freedom
from clinical recurrence was nearly identical for both
treatment groups, p=0.19 (Table V). It is of interest to
analyze DFS by pathological stage, and Gleason score
(Table VI). The data are similar for both treatment
groups. The 5- and 10-year DFS for patients with pT3a
disease and those with Gleason score 2-6 was very good
(Table VI). There was, however, a poor long-term DFS in
patients with seminal vesicle involvement (pT3b) and
in those with high (7-10) Gleason score. The 10-year
probability of DFS (PSA<0.05 ng/ml) in patients with
a high Gleason score and seminal vesicle involvement
was only 11%. Freedom from any recurrence (no clinical
recurrence and PSA <0.05 ng/ml) (FFR) by pathological
stage and Gleason score was analyzed using the Cox
model. The 10-year probability of FFR ranged from
a high of 67% for pT3a, Gleason score 2-6 to a low of
11% for those with pT3b Gleason score 7-10 disease
Table IV. Distribution of patients by clinical stage, pathological stage, Gleason score, 
preoperative PSA and treatment
Parameter RP1+RT2 % RP % Total p-value
Clinical stage
T1 17 4.0 13 6.5 30
T2 339 80.1 177 89.4 516
T3 67 15.8 9 4.5 76 0.001
Pathological stage
pT3a 296 70 180 90 423
pT3b 127 30 19 10 199 <0.0001
Gleason score3
2-4 12 3 6 3 18
5-6 157 37.4 87 44.4 244
7-10 251 59.8 103 52.6 354 0.24
Pre-op PSA4 (ng/ml) 
Mean 15.9 - 8.9 - 13.5
Median 10.0 - 7.4 - 9.1
Minimum 0.05 - 0.05 - 0.05
Maximum 200 - 41 - 200 <0.0001
1 Radical prostatectomy
2 Adjuvant radiotherapy
3 Gleason score was not available in 6 patients
4 PSA was not available in 90 patients treated prior 1987
Table V. Survival, freedom from clinical recurrence, clinical and chemical recurrence by treatment
Parameter % 5-year % 10-year Median (years) N Total N Failure
Survival
RP1 + RT2 92 73 >10 423 71
RP 92 75 >10 199 20
Freedom from clinical recurrence
RP + RT 91 84 >10 423 44
RP 92 91 >10 199 9
Freedom from clinical + PSA recurrence
RP + RT 69 52 >10 423 132
RP 71 60 >10 199 35
1 Radical prostatectomy
2 Adjuvant radiotherapy
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(Table VII). The mean and median time to clinical or
chemical recurrence for all patients was 3.4 and 3.1 years,
respectively. There was no significant difference in time to
any recurrence between the two treatment groups.
A total of 532 (85.5%) had preoperative PSA level
available. The 2- and 5-year survival for patients with
PSA <10 ng/ml was 97 and 91%, respectively. In the
group of >10 and <25 ng/ml it was 99 and 94%,
respectively and in those with PSA > 25 ng/ml it was
100 and 94%, respectively, p=0.81. Likewise, there was
no significant difference in the incidence of freedom
from clinical recurrence between the above preoperative
PSA levels. It is of interest, however, that there was
a difference in a probability of FFR with patients
of <10 ng/ml having the 2- and 5-year FFR of 91 and
76%, respectively, as compared to 83 and 56%,
respectively for those with PSA >25 ng/ml, p=0.02. Of
the 142 patients who developed PSA recurrence in
this study the 2- and 5-year survival was 93 and
78% respectively with a median survival of 7.5 years. The
2- and 5-year incidence of freedom from clinical
recurrence in this group of patients was 77 and 59%,
respectively with a median probability of 5.6 years. There
was no difference in survival, FFR and the incidence of
clinical recurrence by the treatment group (RP+RT vs.
RP alone).
At the last follow-up of the 423 RP+RT patients,
353 (83.4%) were alive including 192 (45.4%) who had
PSA <0.05 ng/ml and 6 patients with local recurrence.
Comparison of treatment outcomes between the two
treatment groups is shown in Table VIII. Ultimately, 13
(3%) patients had local recurrence in RP+RT group and
9 (4.5%) patients had a local recurrence in RP alone
group (NS).
Tr e a t m e n t  c o m p l i c a t i o n s
Surgery
There was no surgical mortality recorded in this study.
Major surgical complications were reported in 3.5% of
patients and there was no significant difference in their
incidence between the two treatment groups. All of these
major complications occurred during or soon after
prostatectomy and were successfully managed with an
appropriate treatment in all cases. Relevant details on
surgical complications have been published [33]. Minor
surgical complications were seen in 9% of patients.
Intraoperative blood transfusion was given in 2% an
postoperative an additional 3%. The average hospital
length of stay was 4 days. Continence was assessed at 1
year posttreatment and 80% of patients were fully
continent in either treatment group. Mild stress incon-
tinence was present in approximately 15% of patients
with the remainder having various degrees incontinence.
Very few (<3%) patients were fully incontinent and
required a surgical procedure for correction. There was
no difference in the incidence of incontinence or erectile
function between patients treated with RP+RT and RP
alone. Early and late assessment of sexual potency and
incontinence have been published [34].
Adjuvant radiotherapy
Radiotherapy was very well tolerated treatment by the
423 study patients. Acute complications were common
(66%) but mild and of no clinical significance. They
consisted of symptoms and signs of proctitis in 35% with
mild diarrhea in 29%, urinary obstructive and irritative
signs and symptoms such as frequency, nocturia or dysuria
in 35% and other acute toxicity in 3%. In most of these
patients with acute toxicity no specific therapy was
Table VI. Disease-free survival by pathological stage, Gleason score and treatment
Parameter % 5-year % 10-year Median (years) N Total N-failure
pstage T3a
RP1 + RT2 78 60 >10 296 66
RP 76 63 >10 180 27
pstage T3b
RP + RT 52 35 5.2 129 66
RP 32 – 4.4 17 8
Gleason score 2-6
RP + RT 84 75 >10 169 31
RP 77 63 >10 93 15
Gleason score 7-10
RP + RT 59 - 6.9 253 99
RP 61 - - 101 20
1 Radical prostatectomy
2 Adjuvant radiotherapy
Table VII. Freedom from any recurrence: Cox Model
pstage Gleason % 5 yr C.I. % 10 yr C.I.
pT3a 2-6 82 75-90 67 54-81
pT3a 7-10 67 58-77 43 30-62
pT3b 2-6 81 69-95 64 45-91
pT3b 7-10 35 26-48 11 5-27
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required and the symptoms have not persisted much
beyond the course of radiotherapy. None of these patients
needed hospitalization to treat radiation related toxicity.
No late toxicity of radiotherapy was reported in particular
no urethral stricture or bowel injury, no increased
incidence of erectile dysfunction or incontinence as
compared to the 199 patients treated with RP alone.
Dicussion
In the absence of a randomized trial comparing outcomes
in patients with pT3N0 disease treated with or without
adjuvant radiotherapy is difficult and this study may be of
help to clinicians who have to provide the patient with
specific treatment recommendations. The study patients
were selected for postoperative irradiation by our two
urologists. Their selection process was based on well-
recognized risk factors with RP+RT patients, as expected,
to include those with worse prognostic factors than the
patients in RP alone group. The strength of this study
includes a treatment uniformity used in both surgery and
radiotherapy over a long (>20 years) period of time and
reported outcomes based on a relatively large number of
patients. Additionally, the study patients were treated
with RP+RT or RP alone without any other adjuvant
treatment. Specifically, none of the patients received
neoadjuvant or adjuvant hormonal therapy. The obvious
weakness is a non-randomized nature of this report. Due
to the complexity of designing such a randomized study
for pT3N0 patients its phase in is not expected to be
imminent.
The use of adjuvant RT in pT3N0 patients has
been reported by a number of medical centers [36-44].
The reported treatment results have been excellent in
terms of a sharp reduction in the expected incidence
of local tumor recurrence. The main difference between
the present study and other reports in the literature is
the radiation technique used in our study. Radiation dose
in our study ranged from 45 to 54 Gy with a median dose
of 48 Gy. This is in contrast to the other reports where the
minimum radiation dose was 64 Gy [44]. Additionally, in
our study the treated volume was small (prostatic fossa
and its immediate vicinity) as opposed to whole pelvis
to 40-45 Gy with a boost to a smaller volume in other
published studies. In spite of these differences in
treatment techniques, the results of our study are equal or
better to the other published data. This is particularly
evident in our patient treatment tolerance with virtually
no clinically important acute toxicity and no late toxicity
being noted as opposed to other reports [44]. There
is a strong support for the use of approximately 45 Gy
in patients with microscopic residual disease [45]. It
is believed, there is a misunderstanding between two
important terms or definitions, which include microscopic
Table IX. Ranking of important prognostic factors – multivariate
analyses
Prognostic factor for P-value
Survival
Gleason score 0.00002
Pathological stage 0.09
Preoperative PSA 0.34
Clinical recurrence
Gleason score 0.13
Pathological stage 0.002
Preoperative PSA 0.54
Clinical + chemical recurrence
Gleason score 0.0002
Pathological stage <0.00001
Preoperative PSA 0.31
Table VIII. Status of all patients at last follow-up
Status RP1 + RT2 RP Total
N % N % N %
Alive-clinical of disease
PSA <0.05 ng/ml 192 45.4 106 53.3 298 47.9
PSA >0.05 ng/ml 61 14.4 21 10.6 82 13.2
PSA not available 59 14 27 13.6 86 13.8
Alive-clinical recurrence
Local 6 1.4 5 2.5 11 1.8
Distant 15 3.6 2 1.0 17 2.7
Local  + distant 1 0.2 0 0.0 1 0.2
Unknown 1 0.2 0 0.0 1 0.2
Alive-disease status unknown 18 4.3 17 8.5 35 5.6
Dead of other causes 
Local recurrence 5 1.2 3 1.5 8 1.3
Distant metastasis 14 3.3 2 1.0 16 2.6
Local + distant 1 0.2 0 0.0 1 0.2
Unknown 0 0.0 1 0.5 1 0.2
Dead of other causes
PSA<0.05 ng/ml 33 7.8 13 6.5 46 7.4
PSA >0.05ng/ml 17 4.0 2 1.0 19 3.1
1 Radical prostatectomy
2 Adjuvant radiotherapy
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proven or strongly suspected microscopic residual disease
following prostatectomy vs. macroscopic residual disease
or recurrent disease manifested by postoperative rise in
PSA level. In the latter, we would also recommend higher
(64 Gy) radiation dose while in the former such a high
dose is not necessary.
Somewhat of a surprise in our study was a lack of
correlation between preoperative serum PSA level and
survival, especially in those patients with PSA>25 ng/ml.
Such patients are generally expected to have a high
probability of extracapsular disease with frequent lymph
node involvement or even distant metastasis, which are
known to compromise survival. There was, however,
a strong predictive value of PSA>10 ng/ml on disease
free survival.
Conclusions
Patients treated with surgery alone had significantly lower
risk factors than those receiving RP+RT combination
yet there was no significant difference in survival, disease
free survival and the incidence of local failure between the
two treatment groups. Adjuvant radiotherapy was well
tolerated without clinically important toxicity. We
hypothesize that moderate dose of adjuvant radiotherapy
following radical prostatectomy helped to equalize risk
factors in patients with pT3N0 disease. Patients with
seminal vesicle involvement and Gleason score 7-10
disease have a low (11%) probability of 10-year disease
free survival as compared to the patients presenting with
lower Gleason score and no seminal vesicle involvement.
This group of high-risk patients should be targeted for
a trial of systemic management in addition to the local
adjuvant radiotherapy.
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